Skip to main content
Premium Trial:

Request an Annual Quote

DeCode s Shares Recede Slightly from Gains On Positive Drug Data

Click here for an updated version of this article.

NEW YORK, Oct. 19 (GenomeWeb News) - Shares in DeCode Genetics this afternoon slipped to $6.97 from their high of $7.70, reached this morning after the company announced positive results from an ongoing drug trial.

 

Shares in the Icelandic pharmacogenomics company closed at $6.61 on the Nasdaq yesterday.

 

As GenomeWeb News reported, DeCode licensed the drug, which is in early-stage Phase IIa testing, from Bayer last November


Results of the study showed the drug, called DG031, to have significantly reduced levels of two chemical biomarkers associated with arterial inflammation and myocardial infarction risk.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.